| Customization: | Available |
|---|---|
| Application: | Internal Medicine |
| Usage Mode: | Inject |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| product name: | Tazobactam Sodium and piperacillin Sodium for inj. |
| specification: | 4.5g |
| certification: | GMP;ISO9001;ISO14001 |
| shelf life: | 36 months |
1 this product has no synergistic effect on enterococcus faecalis when combined with gentamicin.Synergistic effects with certain cephalosporins may also occur on escherichia coli, pseudomonas aeruginosa, klebsiella and some sensitive strains of proteus.
2 In vitro test, this product can inactivate aminoglycoside drugs by combining with aminoglycoside drugs.When combined with tobramycin, the area under the curve, renal clearance and urinary excretion of tobramycin decreased by 11%, 32% and 38%, respectively, due to the potential inactivation of tobramycin by piperacillin tazobartan.The pharmacokinetics of patients with severe renal insufficiency, such as hemodialysis patients, will change when tobramycin is combined with piperacillin.
adverse reaction:
adverse reaction:
(1) skin reactions: rash, pruritus, etc.(2) gastrointestinal reactions, such as diarrhea, nausea, vomiting, etc.(3) allergic reactions.(4) local reactions: such as injection of local stimulation, pain, phlebitis, thrombophlebitis and edema, etc.(5) other reactions: thrombocytopenia, pancreatitis, fever, fever associated with eosinophilia, elevated serum aminotransferase, etc.These reactions occur when the product is combined with aminoglycoside drugs.
In addition, the following adverse reactions can be seen: (1) diarrhea, constipation, nausea, vomiting, abdominal pain, indigestion, etc.(2) macular papules, herpes, urticaria, eczema, etc.(3) restlessness, dizziness, anxiety, etc.(4) other reactions: rhinitis, dyspnea, etc.
contraindication:
It is contraindicated for those allergic to penicillin, cephalosporin antibiotics or beta-lactamase inhibitors.
usage and dosage:
Add an appropriate amount of this product into 250ml liquid (5% glucose injection or sodium chloride injection) after it is fully dissolved in 20ml diluent (sodium chloride injection or sterilized water for injection) and infuse it intravenously for at least 30 minutes each time for a course of 7-10 days.The course of treatment for hospital-acquired pneumonia lasted from 7 to 14 days.And can be adjusted according to the condition and bacteriological examination results.For adults with normal renal function (creatinine clearance rate of 90ml/min) and children over 12 years of age, one intravenous infusion of 3.375g(with piperacillin 3g and tazobattan O.375g) was performed every 6 hours.When treating pneumonia in hospital, the starting dose was 3.375g once every 4 hours, combined with aminoglycoside drugs.If pseudomonas aeruginosa is not isolated, aminoglycoside drugs can be considered to be discontinued according to the infection degree and condition.For patients with renal insufficiency, the recommended dosage is shown in the following table: creatinine clearance rate (ml/ min)20~40: 2.25g once every 6 hours, 8g/1.0g per day;20. For hemodialysis patients, the maximum dose is 2.25g once every 8 hours, and 0.75g can be added after each hemodialysis.
announcements:
1.Penicillin skin test must be done before medication.
2. Cross allergic reactions: people allergic to cephalosporins, cephalomycin, griseofulvin or penicillamine may also be allergic to this product, and those allergic to one penicillin may be allergic to other penicillin, so people with allergic history of penicillin should avoid using this product.
3. Patients with allergic history, bleeding history, ulcerative colitis, local enteritis or antibiotic related enteritis should be used with caution;Renal function should be reduced appropriately.
4. This product contains sodium, and patients who need to control salt intake should regularly check serum electrolyte levels when using this product: for patients who also receive cytotoxic drugs or diuretics, be alert to the possibility of hypokalemia.
Coagulation time should be measured before or during the application of this product in patients with renal dysfunction.Once bleeding occurs, it should be stopped immediately.
Fecal examination, culture of clostridium difficile and cytotoxin analysis of pseudomembranous enteritis should be performed.
7 for liver and renal insufficiency, piperacillin concentration should be monitored to adjust the dose.
Hematopoietic function should be checked regularly, especially for patients with a course of treatment ≥21 days.
9. Existing clinical research data indicate that the efficacy of this product for hospital lower respiratory tract infection and complex urinary tract infection is not good.
Interference with diagnosis: direct antiglobulin (Coombs) test may be positive during the application of this product, and blood urea nitrogen and serum creatinine increase, hypernatremia, hypokalemia, serum amino transferase and serum lactate dehydrogenase increase, and serum bilirubin increase may also occur.
){kind=link}